CEMPRA, INC. (NASDAQ:CEMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On April 25, 2017, David Moore, our President and Chief Commercial Officer, informed us of his resignation from our employment, to be effective on May 5, 2017. Mr. Moore is resigning to take a senior management position with a global pharmaceutical company.
About CEMPRA, INC. (NASDAQ:CEMP)
Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI). CEMPRA, INC. (NASDAQ:CEMP) Recent Trading Information
CEMPRA, INC. (NASDAQ:CEMP) closed its last trading session 00.00 at 3.85 with 529,861 shares trading hands.
